Why I Don't Like Injectable SLU-PP-332

I've seen alot of posts lately about injectable SLU-PP-332...specifically the DMSO-based solutions floating around. I want to address this directly because I think it's important for anyone in this community doing serious research.

The short answer: injectable SLU-PP-332 in DMSO is a bad idea, and here's why.

The Formulation Problem

SLU-PP-332 is a moderately lipophilic small molecule (MW ~290 Da). DMSO can dissolve it in the vial just fine — but the moment you inject it, it hits aqueous interstitial fluid and the whole game changes. You get rapid dilution, potential supersaturation, and microcrystal formation. Those crystals can lodge in capillaries and tissue, causing sterile inflammation, granulomas, or worse if someone is foolish enough to go IV.

This isn't theoretical. Lipophilic compounds without proper solubilizing excipients, think cyclodextrins, surfactants, lipid nanoparticles, PEG/Tween blends, routinely precipitate post-injection. The published preclinical work (Billon et al., 2023/2024) used carefully controlled pharmaceutical-grade vehicles for IP injection in rodents. Nobody is doing that with gray-market DMSO solutions.

There's No Validated Injectable Protocol

Zero published literature exists on IM, SC, or IV formulations in humans. That means:

Unknown safe injection volume and site
Unknown local tissue tolerance (pain, necrosis risk)
Unknown systemic PK when first-pass metabolism is bypassed
No human safety data - none

The published rodent studies used intraperitoneal injection with pharmaceutical vehicles. That's a long way from someone pinning a DMSO solution subcutaneously.

Bypassing First-Pass May Actually Be a Problem

SLU-PP-332 likely undergoes CYP450 hepatic metabolism — the specific pathways aren't fully characterized yet, but that first-pass filtering is probably doing something useful. Bypass it with injection and you're potentially spiking parent drug concentrations into territory with zero dose-response data to guide you.

SLU-PP-332 is a pan-ERR agonist. Selectivity profile at supra-physiologic concentrations? Unknown. Off-target effects at high systemic exposure? Unknown. That's not a corner I'd want to cut.

The Oral Route Already Works

Preclinical mouse data suggests oral bioavailability in the range of 40–50%. To put that in context, plenty of widely-used drugs sit at 20–40% oral bioavailability and work just fine with dose adjustment. Anecdotal human dosing at 200–400 mg orally is producing reported effects, which is consistent with adequate systemic exposure.

400 mg oral at 40% bioavailability = ~160 mg systemic equivalent. That's a meaningful dose reaching circulation through a route that has at least some established toxicology behind it.

Oral also gives you gradual absorption and a predictable Tmax. Injectable DMSO gives you a bolus spike with no dose-response data and precipitation risk on top of that.

The DMSO Adds Its Own Layer of Risk

Beyond the SLU-PP-332-specific issues, gray-market research compounds aren't manufactured to pharmaceutical sterility or endotoxin standards. Injecting contaminated material can trigger severe inflammatory responses, fever, chills, hypotension, cytokine storm. DMSO's own solvent action combined with a precipitating payload in tissue is a recipe for pain and potentially sterile abscesses.

Conclusion

The oral route isn't a limitation to work around with injection, it's the appropriate delivery method for a compound designed for metabolic and mitochondrial effects where steady-state exposure matters. Injectable DMSO formulation bypasses protective metabolism with unknown consequences, adds precipitation and sterility risk, and offers zero therapeutic advantage.

Stick to oral. Do your research. And always source from suppliers who provide legitimate COAs and third-party testing.

2 comments

StartingMyResearch

skool.com/startingmyresearch

Peptide Science Simplified. The latest research and education for peptides, biohacking, longevity from beginner to expert.

Leaderboard (30-day)